TABLE 3.

AHR, IgE, and LALN Cellularity Following Long-Term Pulmonary Exposure to 4-OPA

			AHR (Penh)
4-OPA (vol/vol)	Total IgE (ng/ml)	LALN cellularity (cells/node × 106)	0 mg/ml MCh	10 mg/ml MCh	25 mg/ml MCh	50 mg/ml MCh
0%a	393 ± 107	0.57 ± 0.10	1.11 ± 0.04	1.45 ± 0.13	2.95 ± 0.54	4.27 ± 0.87
1%/1%	738 ± 50	2.24 ± 0.49**	2.46 ± 0.70	4.27 ± 0.67*	5.41 ± 1.36**	6.05 ± 1.34
5%/1%	866 ± 322	1.80 ± 0.13*	2.19 ± 0.18	3.36 ± 0.53	4.29 ± 0.40	5.12 ± 0.31
10%/1%	950 ± 207	2.85 ± 0.62**	1.39 ± 0.19	2.44 ± 0.35	4.13 ± 0.53	6.05 ± 1.18
10% Dermalb	627 ± 69	1.17 ± 0.11	1.11 ± 0.70	1.45 ± 2.48	2.96 ± 2.43	4.23 ± 0.72
1% aspirationc	592 ± 112	2.40 ± 0.42**	1.54 ± 0.22	2.59 ± 0.22	5.44 ± 0.76	7.49 ± 1.05

Note. Values represent the mean ± SE derived from 7 animals per group; dermal exposure concentration/pulmonary exposure concentration.

^aRepresents vehicle control (no dermal or pulmonary exposure)

^bRepresents dermal control (10% dermal 4-OPA).

^cRepresents aspiration control (1% aspiration of 4-OPA).

Significantly different from vehicle controls: *p ≤ 0.05, **p ≤ 0.01.